Navigation Links
Lentigen Corporation announces Sale of Lentiviral Vector Manufacturing Business and Change of Name to Opus Bio, Inc.
Date:8/14/2014

GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been granted certain rights to deploy lentiviral technology in specified therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.  These rights include specified CAR T-cell based therapies as well as specified therapies for single-gene diseases and disorders.

Chimeric antigen receptor T cell therapy (CAR+ T) technologies have made significant advances during the past several years, as evidenced by consistent clinical results reported by several academic teams.  "We are pleased that Lentigen Corporation has been at the forefront of the lentiviral vector manufacturing innovation that has enabled these advances in the treatment of hematologic malignancies," said David Wetherell, Chairman of Lentigen Corporation.  He added, "this transaction will provide Opus Bio with ongoing access to innovations in lentiviral vector and cell processing technologies, while allowing the company to commit further resources toward the advancement its research and clinical development programs."

Opus Bio intends to make further announcements on the progress of its therapeutic pipeline during the coming months.

Opus Bio is a clinical-stage biotechnology company committed to developing potentially transformative cell therapies for cancer and single gene disorders. The company is backed by Biomark Capital, a life sciences and healthcare investment firm with offices in Greenwich, CT and San Francisco, CA.

Investor and media contact:
Douglas D. Lind, MD
Interim Chief Executive Officer
Opus Bio, Inc.
(203) 769-2348
doug@opusbio.com


'/>"/>
SOURCE Opus Bio, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/17/2017)... February 17, 2017 According ... by Product (Consumables, Service), Type (Safety, Efficacy, Validation), ... Drug Discovery and Development, Disease-Risk) - Global Forecast ... projected to reach USD 53.34 Billion by 2021 ... a CAGR of 13.8% during the forecast period ...
(Date:2/17/2017)... Calif. , Feb. 17, 2017  Protagonist ... detailing data on its oral peptide drug candidates, ... Congress of the European Crohn,s and Colitis Organization ... Barcelona, Spain from February ... posters detail preclinical data on Protagonist drug candidates ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
Breaking Biology Technology:
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):